Jasper Dingemanse
10Patents
2h-index
7Co-inventors
43Inventor score
Filing activity: Mar 12, 2009 → Oct 13, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8785484B2 | Dosing regimen for a selective S1P1 receptor agonist | Human Necessities | 17 | Active |
| US10220023B2 | Dosing regimen for a selective S1P1 receptor agonist | Human Necessities | 7 | Active |
| US10251867B2 | Dosing regimen for a selective S1P1 receptor agonist | Human Necessities | 1 | Active |
| US10836754B2 | Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | Physics | 1 | Active |
| US11390615B2 | Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox | Physics | 1 | Active |
| US12336980B2 | Dosing regimen for a selective S1P1 receptor agonist | Human Necessities | 0 | Active |
| US11834443B2 | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | Physics | 0 | Active |
| US10857134B2 | Dosing regimen for a selective S1P1 receptor agonist | Human Necessities | 0 | Active |
| US10660880B2 | Dosing regimen for a selective S1P1 agonist | Human Necessities | 0 | Active |
| US11771683B2 | Dosing regimen for a selective S1P1 receptor agonist | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.